Spark Therapeutics Stock Price, News & Analysis (NASDAQ:ONCE)

$54.50 -0.49 (-0.89 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$54.50
Today's Range$54.02 - $55.23
52-Week Range$41.06 - $91.75
Volume472,492 shs
Average Volume707,191 shs
Market Capitalization$2.02 billion
P/E Ratio-7.57
Dividend YieldN/A
Beta3.02

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ONCE
CUSIPN/A
Phone215-220-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio15.80%
Quick Ratio15.80%

Price-To-Earnings

Trailing P/E Ratio-7.56944444444444
Forward P/E Ratio-7.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.18 million
Price / Sales99.95
Cash FlowN/A
Price / CashN/A
Book Value$10.73 per share
Price / Book5.08

Profitability

Trailing EPS($7.20)
Net Income$-123,650,000.00
Net Margins-1,090.11%
Return on Equity-60.01%
Return on Assets-53.26%

Miscellaneous

Employees213
Outstanding Shares37,010,000

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.79) by $0.11. The biotechnology company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm's revenue for the quarter was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($1.07) earnings per share. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2018?

19 brokerages have issued 1 year price targets for Spark Therapeutics' shares. Their forecasts range from $40.00 to $113.00. On average, they anticipate Spark Therapeutics' stock price to reach $73.94 in the next year. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. Mizuho analysts commented, "We see strong potential for the product in addressing the inherited retinal disease (IRD) market. We are also excited about the hemophilia B program. The company’s hemophilia A program, however, remains to be proven. Recent data was below expectations and we await the anticipated update on the program in 2Q/3Q18 to potentially give greater credit to this indication. We are initiating with a Buy rating and a $79 PT. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these ground-breaking, one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s Luxturna product. FDA approval of Luxturna. In December 2017, Spark’s lead product, Luxturna, gained FDA approval for the treatment of inherited retinal disease." (2/12/2018)
  • 2. Cantor Fitzgerald analysts commented, "We believe Spark’s licensing and supply agreement with Novartis (NVS – Not Covered) for LUXTURNA’s ex-U.S. rights further emphasizes the significant value of the approved gene therapy’s commercial opportunity." (1/24/2018)
  • 3. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
  • 4. Cowen Inc analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
  • 5. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board (Age 63)
  • Katherine A. High M.D., President, Chief Scientific Officer, Director (Age 65)
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director (Age 38)
  • Stephen W. Webster, Chief Financial Officer (Age 56)
  • John P Furey, Chief Operating Officer (Age 52)
  • Federico Mingozzi Ph.D., Chief Scientific Officer
  • Joseph W. La Barge Esq., General Counsel (Age 45)
  • Daniel R. Faga, Chief Business Officer (Age 37)
  • Robert J. Perez, Director (Age 52)
  • Lars G. Ekman M.D., Ph.D., Independent Director (Age 67)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.16%), Clearbridge Investments LLC (1.86%), Rock Springs Capital Management LP (1.66%), Gilder Gagnon Howe & Co. LLC (1.48%), Rockefeller Financial Services Inc. (0.96%) and Geode Capital Management LLC (0.75%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Wells Fargo & Company MN, Quantitative Investment Management LLC, Sectoral Asset Management Inc, American Century Companies Inc., Bank of New York Mellon Corp, Fred Alger Management Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Rockefeller Financial Services Inc., OppenheimerFunds Inc., Macquarie Group Ltd., Spark Investment Management LLC, Element Capital Management LLC, Sabby Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $54.50.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $2.02 billion and generates $20.18 million in revenue each year. The biotechnology company earns $-123,650,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Spark Therapeutics employs 213 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 Market St Ste 1300, PHILADELPHIA, PA 19104-5543, United States. The biotechnology company can be reached via phone at 215-220-9300 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  551
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spark Therapeutics (NASDAQ:ONCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.722.822.75
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $73.94$76.06$91.50$84.55
Price Target Upside: 34.94% upside47.60% upside31.92% upside7.07% upside

Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History

Price Target History for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018JPMorgan Chase & Co.DowngradeOverweight -> Neutral$62.00 -> $60.00LowView Rating Details
2/12/2018MizuhoInitiated CoverageBuy -> Buy$79.00LowView Rating Details
2/8/2018Royal Bank of CanadaReiterated RatingOutperform -> Outperform$65.00HighView Rating Details
1/25/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$64.00 -> $66.00MediumView Rating Details
1/25/2018WedbushReiterated RatingUnderperform -> Positive$35.00 -> $40.00MediumView Rating Details
1/24/2018Cantor FitzgeraldReiterated RatingBuy$105.00MediumView Rating Details
1/23/2018BarclaysReiterated RatingOverweight -> Buy$61.00 -> $64.00LowView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$61.00MediumView Rating Details
1/3/2018Raymond James FinancialSet Price TargetBuy$66.00HighView Rating Details
1/4/2018SunTrust BanksBoost Price TargetBuy$113.00HighView Rating Details
12/14/2017Goldman Sachs GroupDowngradeBuy -> Neutral$106.00 -> $58.00LowView Rating Details
12/13/2017Sanford C. BernsteinSet Price TargetBuy$90.00 -> $71.00MediumView Rating Details
12/12/2017Chardan CapitalLower Price TargetBuy -> Buy$100.00 -> $60.00HighView Rating Details
12/12/2017Leerink SwannDowngradeOutperform -> Market Perform$49.00HighView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy -> Buy$92.00 -> $101.00N/AView Rating Details
10/10/2017CowenReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$83.00HighView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Spark Therapeutics (NASDAQ:ONCE) Earnings History and Estimates Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.79)($1.90)$1.40 million$1.90 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Spark Therapeutics (NASDAQ:ONCE) Earnings Estimates

2018 EPS Consensus Estimate: ($5.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($1.88)$1.01($1.08)
Q2 20185($1.88)($1.40)($1.61)
Q3 20185($1.71)($0.82)($1.30)
Q4 20184($1.51)($1.09)($1.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.30%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2017John FureyCOOSell18$46.33$833.94View SEC Filing  
12/8/2017John FureyCOOBuy18$73.48$1,322.64View SEC Filing  
11/28/2017Katherine A HighInsiderSell5,000$71.32$356,600.00215,000View SEC Filing  
11/16/2017Stephen W WebsterCFOSell10,000$70.14$701,400.0012,500View SEC Filing  
11/13/2017Barge Joseph LaInsiderSell5,500$71.44$392,920.008,146View SEC Filing  
11/13/2017Jeffrey D MarrazzoCEOSell20,000$71.54$1,430,800.00250,000View SEC Filing  
11/9/2017Barge Joseph LaInsiderSell3,309$71.31$235,964.798,146View SEC Filing  
10/31/2017Katherine A HighInsiderSell5,000$83.30$416,500.00215,000View SEC Filing  
10/24/2017Daniel FagaInsiderSell7,500$80.96$607,200.006,000View SEC Filing  
10/20/2017Daniel FagaInsiderSell6,000$79.95$479,700.006,000View SEC Filing  
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00215,000View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.003,928,707View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.001,500View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.006,000View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.003,000View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.0010,825View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00220,000View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50251,350View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.0012,500View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00245,000View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50258,650View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.444,837View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00220,000View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.003,000View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00235,669View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.004,500View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00220,000View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00230,534View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00220,000View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.0010,163View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.009,567View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00212,060View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.004,398View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60212,060View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.004,398View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.0010,325View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.0010,325View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.008,325View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00210,000View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00235,000View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.008,325View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00240,000View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00220,500View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.005,768,707View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80236,971View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00240,000View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00230,100View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00242,290View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60242,348View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20246,017View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44242,348View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66246,017View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00235,000View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.0019,716View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.008,325View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.006,768,707View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00235,000View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00270,100View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.0012,825View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.0022,500View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00255,000View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.0019,716View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.907,768,707View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.007,900,212View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00280,000View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00290,000View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00300,000View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00300,000View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00230,000View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00305,000View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.005,383View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.002,500View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.005,000View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spark Therapeutics (NASDAQ ONCE) News Headlines

Source:
DateHeadline
JPMorgan Chase & Co. Lowers Spark Therapeutics (ONCE) to NeutralJPMorgan Chase & Co. Lowers Spark Therapeutics (ONCE) to Neutral
www.americanbankingnews.com - February 15 at 12:52 AM
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 am ET to Discuss 2017 Results and Recent ... - GlobeNewswire (press release)Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 am ET to Discuss 2017 Results and Recent ... - GlobeNewswire (press release)
globenewswire.com - February 14 at 7:19 AM
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business HighlightsSpark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
finance.yahoo.com - February 13 at 3:28 PM
Spark Therapeutics (ONCE) Earns Buy Rating from Analysts at MizuhoSpark Therapeutics (ONCE) Earns Buy Rating from Analysts at Mizuho
www.americanbankingnews.com - February 12 at 8:28 PM
Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Royal Bank of CanadaSpark Therapeutics (ONCE) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - February 11 at 12:30 PM
Spark Therapeutics to Participate in Multiple Conferences in February - GlobeNewswire (press release)Spark Therapeutics to Participate in Multiple Conferences in February - GlobeNewswire (press release)
globenewswire.com - February 7 at 7:06 AM
 Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Announce Quarterly Sales of $9.53 Million Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Announce Quarterly Sales of $9.53 Million
www.americanbankingnews.com - February 6 at 9:14 AM
Spark Therapeutics to Participate in Multiple Conferences in FebruarySpark Therapeutics to Participate in Multiple Conferences in February
finance.yahoo.com - February 5 at 3:26 PM
ValuEngine Downgrades Spark Therapeutics (ONCE) to Strong SellValuEngine Downgrades Spark Therapeutics (ONCE) to Strong Sell
www.americanbankingnews.com - February 4 at 6:36 PM
Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.73 Per ShareSpark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - February 4 at 3:18 AM
Spark Therapeutics Inc (ONCE) Receives Average Rating of "Buy" from BrokeragesSpark Therapeutics Inc (ONCE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 3:34 PM
Spark Therapeutics Inc (ONCE) Expected to Earn Q1 2018 Earnings of $1.01 Per ShareSpark Therapeutics Inc (ONCE) Expected to Earn Q1 2018 Earnings of $1.01 Per Share
www.americanbankingnews.com - January 29 at 2:06 AM
Spark Therapeutics Inc to Post Q1 2018 Earnings of ($1.47) Per Share, Wedbush Forecasts (ONCE)Spark Therapeutics Inc to Post Q1 2018 Earnings of ($1.47) Per Share, Wedbush Forecasts (ONCE)
www.americanbankingnews.com - January 29 at 2:06 AM
Spark Therapeutics (ONCE) Rating Reiterated by WedbushSpark Therapeutics (ONCE) Rating Reiterated by Wedbush
www.americanbankingnews.com - January 27 at 6:40 PM
Novartis Gets Spark Therapeutics' Luxterna License Outside USNovartis Gets Spark Therapeutics' Luxterna License Outside US
finance.yahoo.com - January 26 at 3:28 PM
Spark Therapeutics (ONCE) Price Target Increased to $66.00 by Analysts at BMO Capital MarketsSpark Therapeutics (ONCE) Price Target Increased to $66.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - January 25 at 11:48 PM
Novartis, Spark in vision-loss gene therapy dealNovartis, Spark in vision-loss gene therapy deal
www.marketwatch.com - January 25 at 6:58 AM
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
finance.yahoo.com - January 25 at 6:58 AM
Cantor Fitzgerald Reiterates "Buy" Rating for Spark Therapeutics (ONCE)Cantor Fitzgerald Reiterates "Buy" Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - January 24 at 8:34 PM
Barclays Reiterates "Buy" Rating for Spark Therapeutics (ONCE)Barclays Reiterates "Buy" Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - January 23 at 10:06 PM
$9.53 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter$9.53 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - January 20 at 12:44 PM
Juno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing DebatesJuno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing Debates
finance.yahoo.com - January 18 at 11:15 AM
Q1 2018 EPS Estimates for Spark Therapeutics Inc Reduced by Wedbush (ONCE)Q1 2018 EPS Estimates for Spark Therapeutics Inc Reduced by Wedbush (ONCE)
www.americanbankingnews.com - January 18 at 9:42 AM
Spark Therapeutics (ONCE) Now Covered by Credit Suisse GroupSpark Therapeutics (ONCE) Now Covered by Credit Suisse Group
www.americanbankingnews.com - January 17 at 5:24 PM
Analyst: Spark Therapeutics $850K Blindness Drug Has Smaller-Than-Expected MarketAnalyst: Spark Therapeutics' $850K Blindness Drug Has Smaller-Than-Expected Market
www.benzinga.com - January 16 at 10:19 AM
Drugmakers see a pricing blueprint in an $850,000 gene therapy - ReutersDrugmakers see a pricing blueprint in an $850,000 gene therapy - Reuters
www.reuters.com - January 13 at 4:27 PM
Sparks price for Luxturna blindness gene therapy too high: ICER - ReutersSpark's price for Luxturna blindness gene therapy too high: ICER - Reuters
www.reuters.com - January 13 at 4:27 PM
Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapyAnalysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy
finance.yahoo.com - January 13 at 10:10 AM
Drugmakers see a pricing blueprint in an $850,000 gene therapyDrugmakers see a pricing blueprint in an $850,000 gene therapy
finance.yahoo.com - January 12 at 4:28 PM
Sparks planned price for Luxturna gene therapy for rare blindness too high -ICERSpark's planned price for Luxturna gene therapy for rare blindness too high -ICER
finance.yahoo.com - January 12 at 4:28 PM
Non-Profit Says $850,000 Gene Therapy Is At Least Twice As Expensive As It Should BeNon-Profit Says $850,000 Gene Therapy Is At Least Twice As Expensive As It Should Be
finance.yahoo.com - January 12 at 4:28 PM
Sparks price for Luxturna blindness gene therapy too high: ICERSpark's price for Luxturna blindness gene therapy too high: ICER
finance.yahoo.com - January 12 at 4:28 PM
Spark Therapeutics Inc (ONCE) Short Interest UpdateSpark Therapeutics Inc (ONCE) Short Interest Update
www.americanbankingnews.com - January 12 at 3:14 AM
Head-To-Head Contrast: Xenon Pharmaceuticals (XENE) versus Spark Therapeutics (ONCE)Head-To-Head Contrast: Xenon Pharmaceuticals (XENE) versus Spark Therapeutics (ONCE)
www.americanbankingnews.com - January 10 at 8:02 AM
FY2018 Earnings Forecast for Spark Therapeutics Inc (ONCE) Issued By SunTrust BanksFY2018 Earnings Forecast for Spark Therapeutics Inc (ONCE) Issued By SunTrust Banks
www.americanbankingnews.com - January 8 at 10:02 AM
William Blair Equities Analysts Lower Earnings Estimates for Spark Therapeutics Inc (ONCE)William Blair Equities Analysts Lower Earnings Estimates for Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - January 8 at 6:02 AM
Spark Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (ONCE)Spark Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (ONCE)
www.americanbankingnews.com - January 8 at 5:02 AM
Raymond James Financial Reiterates $66.00 Price Target for Spark Therapeutics (ONCE)Raymond James Financial Reiterates $66.00 Price Target for Spark Therapeutics (ONCE)
www.americanbankingnews.com - January 8 at 12:44 AM
Why This Gene Therapy Pioneer Crashed 29.8% in DecemberWhy This Gene Therapy Pioneer Crashed 29.8% in December
finance.yahoo.com - January 6 at 4:34 PM
Spark Therapeutics Inc (ONCE) Forecasted to Post FY2022 Earnings of $7.91 Per ShareSpark Therapeutics Inc (ONCE) Forecasted to Post FY2022 Earnings of $7.91 Per Share
www.americanbankingnews.com - January 5 at 8:08 PM
Spark Therapeutics Inc (ONCE) Given Consensus Recommendation of "Buy" by BrokeragesSpark Therapeutics Inc (ONCE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 1:54 PM
Spark Therapeutics (ONCE) Appoints Robert Perez to BoardSpark Therapeutics (ONCE) Appoints Robert Perez to Board
www.streetinsider.com - January 4 at 4:38 PM
Spark Therapeutics vision-loss gene therapy to cost $850,000 per patientSpark Therapeutics' vision-loss gene therapy to cost $850,000 per patient
finance.yahoo.com - January 4 at 10:15 AM
Spark to charge $850,000 per patient for blindness gene therapySpark to charge $850,000 per patient for blindness gene therapy
finance.yahoo.com - January 4 at 10:15 AM
Wall Street Reacts To Spark Therapeutics $850K Genetic Blindness TreatmentWall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment
finance.yahoo.com - January 4 at 10:15 AM
Drug Firm Spark Therapeutics Will Charge $850,000 for Vision-Loss Gene TherapyDrug Firm Spark Therapeutics Will Charge $850,000 for Vision-Loss Gene Therapy
finance.yahoo.com - January 4 at 10:15 AM
Spark Therapeutics Announces Addition of Robert J. Perez to Board of DirectorsSpark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
finance.yahoo.com - January 4 at 10:15 AM
Spark Therapeutics (ONCE) PT Raised to $113.00Spark Therapeutics (ONCE) PT Raised to $113.00
www.americanbankingnews.com - January 4 at 9:00 AM
Wall Street Reacts To Spark Therapeutics $850K Genetic Blindness Treatment - BenzingaWall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment - Benzinga
www.benzinga.com - January 3 at 4:39 PM
Spark Should Spark a Pricing TrendSpark Should Spark a Pricing Trend
finance.yahoo.com - January 3 at 4:39 PM

SEC Filings

Spark Therapeutics (NASDAQ:ONCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spark Therapeutics (NASDAQ ONCE) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.